Study of chemo plus immunotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that has not spread to distant organs.
- You have not had any previous cancer treatment (like chemotherapy, radiation, or immunotherapy).
- You are in good overall health (able to do daily activities without help).
- Your blood, liver, kidney, and heart function must be within acceptable ranges.
- You do not have other serious conditions like active infections, autoimmune diseases, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
Hear when a new Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.